Showing results (41-50 of 54) with videos related to

Sort By:
Pageof 6
NPJ Vaccines|April 7, 2023
Glycosylated nanoparticle-based PfCSP vaccine confers long-lasting antibody responses and sterile protection in mouse malaria modelJulia Ludwig, Stephen W Scally, Giulia Costa, et al.
Scientific Reports|August 11, 2017
The anti-influenza M2e antibody response is promoted by XCR1 targeting in pig skinCharlotte Deloizy, Even Fossum, Christophe Barnier-Quer, et al.
Cell Reports. Medicine|November 1, 2023
Emulsion and liposome-based adjuvanted R21 vaccine formulations mediate protection against malaria through distinct immune mechanismsSören Reinke, Eirini Pantazi, Gabrielle R Chappell, et al.
Plos Neglected Tropical Diseases|October 21, 2009
Immunogenic salivary proteins of Triatoma infestans: development of a recombinant antigen for the detection of low-level infestation of triatominesAlexandra Schwarz, Stefan Helling, Nicolas Collin, et al.
Plos Neglected Tropical Diseases|September 9, 2024
Correction: Immunogenic Salivary Proteins of Triatoma infestans: Development of a Recombinant Antigen for the Detection of Low-Level Infestation of TriatominesAlexandra Schwarz, Stefan Helling, Nicolas Collin, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|July 3, 2019
Electroporation of a nanoparticle-associated DNA vaccine induces higher inflammation and immunity compared to its delivery with microneedle patches in pigsCindy Bernelin-Cottet, Céline Urien, Joanne McCaffrey, et al.
Plos Neglected Tropical Diseases|March 31, 2010
Discovery of markers of exposure specific to bites of Lutzomyia longipalpis, the vector of Leishmania infantum chagasi in Latin AmericaClarissa Teixeira, Regis Gomes, Nicolas Collin, et al.
Scientific Reports|January 14, 2016
SALO, a novel classical pathway complement inhibitor from saliva of the sand fly Lutzomyia longipalpisViviana P Ferreira, Vladimir Fazito Vale, Michael K Pangburn, et al.
Vaccine|September 16, 2025
Safety and immunogenicity of COVAC-2, a Sepivac SWE™ adjuvanted SARS-CoV-2 recombinant protein vaccine in healthy adults; a randomized controlled first-in-human dose-escalation trialGlenn Hamonic, Elodie Pastural, Supriya Arora, et al.
Vaccine|May 20, 2024
Efficacy of a stable broadly protective subunit vaccine platform against SARS-CoV-2 variants of concernRavendra Garg, Qiang Liu, Jill Van Kessel, et al.
Pageof 6